Mechanisms of HGF/Met Signaling to Brk and Sam68 in Breast Cancer Progression

Hormones and Cancer

Volumn 3, Issue 1-2, 2012, Pages 14-25

  Locatelli, Alessia ^a   Lofgren, Kristopher A ^a   Daniel, Andrea R ^a   Castro, Nancy E ^a   Lange, Carol A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Brk; Cell migration; Erk5; HGF; Met; PTK6; Sam68

Indexed keywords

CD44V6 ANTIGEN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEFITINIB; MESSENGER RNA; METHYLNITRONITROSOGUANIDINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 7; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN BRK; PROTEIN GAB1; PROTEIN SAM68; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; STAT PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHROMOSOME 1; CHROMOSOME 7Q; CHROMOSOME TRANSLOCATION; COLON ADENOCARCINOMA; COLORECTAL CANCER; EMBRYO DEVELOPMENT; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROBLAST; G1 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK CARCINOMA; HUMAN; INTRADUCTAL CARCINOMA; LIVER REGENERATION; LIVER RESECTION; METASTASIS; MITOSIS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REVIEW; RNA BINDING; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SRC HOMOLOGY DOMAIN; TISSUE INJURY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST; BREAST NEOPLASMS; CELL MOVEMENT; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 7; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MET; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TYROSINE;

EID: 84856669345     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-011-0097-z     Document Type: Review

References (150)

1. Nakamura T et al (2000) Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 106(12): 1511-1519.
2. Huh CG et al (2004) Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A 101: 4477-4482.
3. Edakuni G et al (2001) Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 51(3): 172-178.
4. Jin L et al (1997) Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 79(4): 749-760.
5. Tuck AB et al (1996) Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 148(1): 225-232.
6. Nakamura T, Nawa K, Ichihara A (1984) Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 122(3): 1450-1459.
7. Russell WE, McGowan JA, Bucher NL (1984) Partial characterization of a hepatocyte growth factor from rat platelets. J Cell Physiol 119(2): 183-192.
8. Stoker M et al (1987) Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327: 239-242.
9. Weidner KM et al (1991) Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A 88(16): 7001-7005.
10. Fukuyama R et al (1991) Regional localization of the hepatocyte growth factor (HGF) gene to human chromosome 7 band q21. 1. Genomics 11(2): 410-415.
11. Donate LE et al (1994) Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci 3(12): 2378-2394.
12. Nakamura T (1989) Molecular characterization of hepatocyte growth factor (HGF). Seikagaku 61(10): 1243-1247.
13. Miyazawa K, Shimomura T, Kitamura N (1996) Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J Biol Chem 271(7): 3615-3618.
14. Shimomura T et al (1993) Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem 268(30): 22927-22932.
15. Mars WM, Zarnegar R, Michalopoulos GK (1993) Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 143(3): 949-958.
16. Naldini L et al (1995) Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 270(2): 603-611.
17. Lee SL, Dickson RB, Lin CY (2000) Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275(47): 36720-36725.
18. Shimomura T et al (1995) Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator. Eur J Biochem 229(1): 257-261.
19. Jiang W et al (1999) Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 29(3): 209-248.
20. Trusolino L, Comoglio PM (2002) Scatter factor and semaphorin receptors: cell signaling for invasive growth. Nat Rev Cancer 2: 289-300.
21. Jiang WG, Hiscox S (1997) Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histol Histopathol 12(2): 537-555.
22. Bottaro DP et al (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251(4995): 802-804.
23. Naldini L et al (1991) Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 6(4): 501-504.
24. Nusrat A et al (1994) Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelial, and induction of wound reapir in a transformed model epithelium. J Clin Invest 93: 2056-2065.
25. Bussolino F et al (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119(3): 629-641.
26. Beilmann M et al (1997) Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood 90(11): 4450-4458.
27. Park M et al (1987) Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A 84(18): 6379-6383.
28. Cooper CS et al (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311(5981): 29-33.
29. Park M et al (1986) Mechanism of met oncogene activation. Cell 45(6): 895-904.
30. Abella JV et al (2005) Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 25(21): 9632-9645.
31. Peschard P et al (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8(5): 995-1004.
32. Qi J et al (2011) Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 71(3): 1081-1091.
33. Ponzetto C et al (1994) A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77(2): 261-271.
34. Royal I, Fournier TM, Park M (1997) Differential requirement of Grb2 and PI3-kinase in HGF/SF-induced cell motility and tubulogenesis. J Cell Physiol 173(2): 196-201.
35. Xiao GH et al (2001) Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A 98(1): 247-252.
36. Birchmeier C et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12): 915-925.
37. Boccaccio C et al (1998) Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391(6664): 285-288.
38. Thomas RM et al (2007) The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 67(13): 6075-6082.
39. Follenzi A et al (2000) Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19(27): 3041-3049.
40. Conrotto P et al (2004) Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23(30): 5131-5137.
41. Wang X et al (2002) A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell 9(2): 411-421.
42. van der Voort R et al (1999) Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem 274(10): 6499-6506.
43. Orian-Rousseau V et al (2002) CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16(23): 3074-3086.
44. Locatelli A, Lange CA (2011) Met receptors induce Sam68-dependent cell migration by activation of alternate extracellular signal-regulated kinase family members. J Biol Chem 286(24): 21062-21072.
45. Wu ST et al (2003) Correlation of CD44v5 expression with invasiveness and prognosis in renal cell carcinoma. J Formos Med Assoc 102(4): 229-233.
46. Birchmeier C, Gherardi E (1998) Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 8(10): 404-410.
47. Bladt F et al (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376(6543): 768-771.
48. Dietrich S et al (1999) The role of SF/HGF and c-Met in the development of skeletal muscle. Development 126(8): 1621-1629.
49. Chmielowiec J et al (2007) c-Met is essential for wound healing in the skin. J Cell Biol 177: 151-162.
50. Borowiak M et al (2004) Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A 101(29): 10608-10613.
51. Michalopoulos GK, DeFrances MC (1997) Liver regeneration. Science 276(5309): 60-66.
52. Taub R (2004) Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 5(10): 836-847.
53. Cowin AJ et al (2001) Hepatocyte growth factor and macrophage-stimulating protein are upregulated during excisional wound repair in rats. Cell Tissue Res 306(2): 239-250.
54. Kawaida K et al (1994) Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci U S A 91(10): 4357-4361.
55. Ohmichi H, Matsumoto K, Nakamura T (1996) In vivo mitogenic action of HGF on lung epithelial cells: pulmotrophic role in lung regeneration. Am J Physiol 270(6 Pt 1): L1031-L1039.
56. Yoshida S et al (2003) Neutralization of hepatocyte growth factor leads to retarded cutaneous wound healing associated with decreased neovascularization and granulation tissue formation. J Invest Dermatol 120(2): 335-343.
57. Nayeri F et al (2002) Hepatocyte growth factor may accelerate healing in chronic leg ulcers: a pilot study. J Dermatolog Treat 13(2): 81-86.
58. Nayeri F et al (2005) Hepatocyte growth factor; expression, concentration and biological activity in chronic leg ulcers. J Dermatol Sci 37(2): 75-85.
59. Bevan D et al (2004) Diverse and potent activities of HGF/SF in skin wound repair. J Pathol 203(3): 831-838.
60. Niranjan B et al (1995) HGF/SF: a potent cytokine for mammary growth, morphogenesis and development. Development 121(9): 2897-2908.
61. Montesano R et al (1991) Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67(5): 901-908.
62. Ferracini R et al (1995) The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10(4): 739-749.
63. Lai AZ, Abella JV, Park M (2009) Crosstalk in Met receptor oncogenesis. Trends Cell Biol 19(10): 542-551.
64. Natali PG et al (1996) Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer 69(3): 212-217.
65. Di Renzo MF et al (1994) Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer 58(5): 658-662.
66. Takeo S et al (2001) Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis. Cancer Genet Cytogenet 130(2): 127-132.
67. Olivero M et al (1996) Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 74(12): 1862-1868.
68. Di Renzo MF et al (1995) Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 55(5): 1129-1138.
69. Humphrey PA et al (1995) Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147(2): 386-396.
70. Ivan M et al (1997) Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14(20): 2417-2423.
71. Gambarotta G et al (1996) Ets up-regulates MET transcription. Oncogene 13(9): 1911-1917.
72. Boon EM et al (2002) Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 62(18): 5126-5128.
73. Graveel CR et al (2009) Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A 106(31): 12909-12914.
74. Ponzo MG et al (2009) Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 106(31): 12903-12908.
75. Ostrander JH et al (2007) Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res 67(9): 4199-4209.
76. Chen HY et al (2004) Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol 24(24): 10558-10572.
77. Llor X et al (1999) BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res 5(7): 1767-1777.
78. Castro NE, Lange CA (2010) Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast Cancer Res 12(4): R60.
79. Mitchell PJ et al (1994) Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene 9(8): 2383-2390.
80. Lee H et al (1998) Exon-intron structure of the human PTK6 gene demonstrates that PTK6 constitutes a distinct family of non-receptor tyrosine kinase. Mol Cells 8(4): 401-407.
81. Derry JJ et al (2003) Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 22(27): 4212-4220.
82. Schmandt RE et al (2006) The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther 5(9): 1136-1141.
83. Lin HS et al (2004) Identification of tyrosine kinases overexpressed in head and neck cancer. Arch Otolaryngol Head Neck Surg 130(3): 311-316.
84. Easty DJ et al (1997) Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma. Int J Cancer 71(6): 1061-1065.
85. Qiu H, Miller WT (2002) Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. J Biol Chem 277(37): 34634-34641.
86. Serfas MS, Tyner AL (2003) Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncol Res 13(6-10): 409-419.
87. Kamalati T et al (1996) Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem 271(48): 30956-30963.
88. Kamalati T et al (2000) Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene 19(48): 5471-5476.
89. Xiang B et al (2008) Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc Natl Acad Sci U S A 105(34): 12463-12468.
90. Vasioukhin V, Tyner AL (1997) A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation. Proc Natl Acad Sci U S A 94(26): 14477-14482.
91. Derry JJ et al (2000) Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability. Mol Cell Biol 20(16): 6114-6126.
92. Mitchell PJ, Sara EA, Crompton MR (2000) A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK. Oncogene 19(37): 4273-4282.
93. Ikeda O et al (2009) STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation. Biochem Biophys Res Commun 384(1): 71-75.
94. Haegebarth A et al (2004) The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2. J Biol Chem 279(52): 54398-54404.
95. Lukong KE, Richard S (2008) Breast tumor kinase BRK requires kinesin-2 subunit KAP3A in modulation of cell migration. Cell Signal 20(2): 432-442.
96. Shen CH et al (2008) Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Res 68(19): 7779-7787.
97. Lukong KE, Huot ME, Richard S (2009) BRK phosphorylates PSF promoting its cytoplasmic localization and cell cycle arrest. Cell Signal 21(9): 1415-1422.
98. Palka-Hamblin HL et al (2010) Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6. J Cell Sci 123(Pt 2): 236-245.
99. Zheng Y et al (2010) Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol 30(17): 4280-4292.
100. Liu L et al (2006) Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene 25(35): 4904-4912.
101. Weaver AM, Silva CM (2007) Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. Breast Cancer Res 9(6): R79.
102. Liu X, Robinson GW, Hennighausen L (1996) Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol Endocrinol 10(12): 1496-1506.
103. Philp JA, Burdon TG, Watson CJ (1996) Differential activation of STATs 3 and 5 during mammary gland development. FEBS Lett 396(1): 77-80.
104. Chapman RS et al (1999) Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13(19): 2604-2616.
105. Walker NI, Bennett RE, Kerr JF (1989) Cell death by apoptosis during involution of the lactating breast in mice and rats. Am J Anat 185(1): 19-32.
106. Ostrander JH, Daniel AR, Lange CA (2010) Brk/PTK6 signaling in normal and cancer cell models. Curr Opin Pharmacol 10(6): 662-669.
107. Harvey AJ et al (2009) Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage. Am J Pathol 175(3): 1226-1234.
108. Lofgren KA et al (2011) Mammary gland specific expression of Brk/PTK6 promotes delated involution and tumor formation associated with activation of p38 MAPK. Breast Cancer Res 13(5): R89.
109. Chen T et al (1999) A role for the GSG domain in localizing Sam68 to novel nuclear structures in cancer cell lines. Mol Cell Biol 10: 3015-3033.
110. Vernet C, Artzt K (1997) STAR, a gene family involved in signal transduction and activation of RNA. Trends Genet 13(12): 479-484.
111. Chen T et al (1997) Self-association of the single-KH-domain family members Sam68, GRP33, GLD-1, and Qk1: role of the KH domain. Mol Cell Biol 17(10): 5707-5718.
112. Busa R et al (2007) The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene 26(30): 4372-4382.
113. Taylor SJ, Shalloway D (1994) An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature 368(6474): 867-871.
114. Lin Q, Taylor SJ, Shalloway D (1997) Specificity and determinants of Sam68 RNA binding. Implications for the biological function of K homology domains. J Biol Chem 272(43): 27274-27280.
115. Meyer NH et al (2010) Structural basis for homodimerization of the Src-associated during mitosis, 68-kDa protein (Sam68) Qua1 domain. J Biol Chem 285(37): 28893-28901.
116. Lukong KE et al (2005) Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. J Biol Chem 280(46): 38639-38647.
117. Wang LL, Richard S, Shaw AS (1995) P62 association with RNA is regulated by tyrosine phosphorylation. J Biol Chem 270(5): 2010-2013.
118. Wong G et al (1992) Molecular cloning and nucleic acid binding properties of the GAP-associated tyrosine phosphoprotein p62. Cell 69(3): 551-558.
119. Weng Z et al (1994) Identification of Src, Fyn, and Lyn SH3-binding proteins: implications for a function of SH3 domains. Mol Cell Biol 14(7): 4509-4521.
120. Fumagalli S et al (1994) A target for Src in mitosis. Nature 368(6474): 871-874.
121. Taylor SJ et al (1995) Functional interaction between c-Src and its mitotic target, Sam 68. J Biol Chem 270(17): 10120-10124.
122. Richard S et al (1995) Association of p62, a multifunctional SH2- and SH3-domain-binding protein, with src family tyrosine kinases, Grb2, and phospholipase C gamma-1. Mol Cell Biol 15(1): 186-197.
123. Trub T et al (1997) The role of a lymphoid-restricted, Grb2-like SH3-SH2-SH3 protein in T cell receptor signaling. J Biol Chem 272(2): 894-902.
124. Burd CG, Dreyfuss G (1994) Conserved structures and diversity of functions of RNA-binding proteins. Science 265(5172): 615-621.
125. Cote J et al (2003) Sam68 RNA binding protein is an in vivo substrate for protein arginine N-methyltransferase 1. Mol Biol Cell 14(1): 274-287.
126. Bedford MT et al (2000) Arginine methylation inhibits the binding of proline-rich ligands to Src homology 3, but not WW, domains. J Biol Chem 275(21): 16030-16036.
127. Ishidate T et al (1997) Identification of a novel nuclear localization signal in Sam68. FEBS Lett 409(2): 237-241.
128. Wu J et al (1999) The quaking I-5 protein (QKI-5) has a novel nuclear localization signal and shuttles between the nucleus and the cytoplasm. J Biol Chem 274(41): 29202-29210.
129. Liu K et al (2000) Neoplastic transformation and tumorigenesis associated with sam68 protein deficiency in cultured murine fibroblasts. J Biol Chem 275(51): 40195-40201.
130. Hong W et al (2002) Physical and functional interaction between the transcriptional cofactor cbp and the kh domain protein Sam68. Mol Cancer Res 1(1): 48-55.
131. Matter N, Herrlich P, Konig H (2002) Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420(6916): 691-695.
132. Paronetto MP et al (2007) The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J Cell Biol 176(7): 929-939.
133. Paronetto MP et al (2010) Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res 70(1): 229-239.
134. Song L et al (2010) Sam68 up-regulation correlates with, and its down-regulation inhibits, proliferation and tumourigenicity of breast cancer cells. J Pathol 222(3): 227-237.
135. Barlat I et al (1997) A role for Sam68 in cell cycle progression antagonized by a spliced variant within the KH domain. J Biol Chem 272(6): 3129-3132.
136. Richard S et al (2008) Sam68 haploinsufficiency delays onset of mammary tumorigenesis and metastasis. Oncogene 27(4): 548-556.
137. Rajan P et al (2008) The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. J Pathol 215(1): 67-77.
138. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410(6824): 37-40.
139. Valacca C et al (2010) Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J Cell Biol 191(1): 87-99.
140. Jo M et al (2000) Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275(12): 8806-8811.
141. Bergstrom JD, Westermark B, Heldin NE (2000) Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res 259(1): 293-299.
142. Agarwal S et al (2009) Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer 100(6): 941-949.
143. Khoury H et al (2005) HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell 16(2): 550-561.
144. Engelman JA et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827): 1039-1043.
145. Mueller KL et al (2010) EGFR/Met association regulates EGFR TKI resistance in breast cancer. J Mol Signal 5: 8.
146. Mueller KL et al (2008) Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 68(9): 3314-3322.
147. Fischer OM et al (2004) Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 279(28): 28970-28978.
148. Qiu H, Miller WT (2004) Role of the Brk SH3 domain in substrate recognition. Oncogene 23(12): 2216-2223.
149. Qiu H et al (2005) Interaction between Brk kinase and insulin receptor substrate-4. Oncogene 24(36): 5656-5664.
150. Zhang P et al (2005) Regulated association of protein kinase B/Akt with breast tumor kinase. J Biol Chem 280(3): 1982-1991.